[{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Levalbuterol Hydrochloride","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Lupin Ltd"}]

Find Clinical Drug Pipeline Developments & Deals for Levalbuterol Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Through th acquisition, Lupin expand its portfolio of accretive established products in Europe and Canada, including Xopenex (levalbuterol HCl), a short-acting β₂ adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulm...

                          Brand Name : Xopenex

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 23, 2023

                          Lead Product(s) : Levalbuterol Hydrochloride

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Sponsor : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Sanofi Company Banner